Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects

Mohamed-Eslam F. Mohamed, Sheryl Coppola, Tian Feng, Heidi S. Camp, Elaine Kim, and Ahmed A. Othman†

Upadacitinib is an oral, selective, and reversible inhibitor of Janus kinase 1, which was approved for the treatment for moderate-to-severe rheumatoid arthritis (RA) by the US Food and Drug Administration, the European Medicines Agency, Japan Pharmaceuticals and Medical Devices Agency, and other regulatory agencies. Additionally, upadacitinib is currently being evaluated for the treatment of other autoimmune diseases in several phase 3 clinical trials.1-6 The approved dose of upadacitinib in subjects with moderate to severe RA is 15 mg once daily using an extended-release formulation based on results from phase 3 clinical trials that evaluated both 15 mg and 30 mg once daily doses and demonstrated that upadacitinib 15 mg once daily maximizes efficacy in RA.4-11

Upadacitinib pharmacokinetics have been characterized in healthy subjects and in patient populations for several autoimmune diseases (eg, RA, Crohn disease, ulcerative colitis).9,12-16 Upadacitinib is a nonsensitive substrate of cytochrome P450 (CYP) 3A.12,17 In a clinical cocktail drug interaction study, administration of upadacitinib 30 mg once daily (twice the approved dose in RA) in healthy subjects resulted in a decrease in midazolam area under the plasma concentration–time curve from time 0 to infinity (AUC0−t) by 33% and 23% lower, respectively, when administered with upadacitinib relative to when administered alone. Administration of a single 5-mg dose of rosuvastatin or a single 10-mg dose of atorvastatin had no relevant effect on upadacitinib Cmax or area under the plasma concentration–time curve. These results demonstrated that upadacitinib has no clinically relevant effect on the pharmacokinetics of rosuvastatin and atorvastatin or on substrates transported by OATP1B or breast cancer resistance protein.

Keywords
ABT-494, atorvastatin, BCRP, OATP1B1, P-gp, rosuvastatin, upadacitinib

AbbVie Inc., North Chicago, Illinois, USA

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Submitted for publication 20 January 2021; accepted 28 March 2021.

Corresponding Author:
Mohamed-Eslam F. Mohamed, PhD, FCP, AbbVie, Inc., Clinical Pharmacology and Pharmacometrics, Department R4PK, Building AP31-3, 1 North Waukegan Road, North Chicago, IL 60064
(e-mail: mohamed-eslam.mohamed@abbvie.com)

Dr. Mohamed-Eslam F. Mohamed and Dr. Ahmed A. Othman are Fellows of the American College of Clinical Pharmacology.
† AbbVie was the affiliation of Dr. Othman at the time this research was conducted.
time curve (AUC) and maximum observed plasma concentration (C_max) of 26% when administered with upadacitinib relative to when administered alone. This limited effect on the CYP3A probe substrate midazolam is not expected to be clinically relevant and aligns with the lack of effect of upadacitinib on exposures of levonorgestrel and ethinylestradiol, 2 oral contraceptives that are also CYP3A substrates. No relevant effects on CYP1A2, CYP2C9, CYP2C19, or CYP2D6 activity were observed following upadacitinib dosing in the cocktail drug interaction study. Upadacitinib is a substrate for P-glycoprotein and breast cancer resistance protein (BCRP) based on in vitro assessments; however, modulation of P-glycoprotein and BCRP transporters is not expected to have clinically relevant effects on upadacitinib plasma exposures. Based on in vitro assessments, upadacitinib is not expected to inhibit the transporters BCRP and organic anion transporting polypeptide (OATP) 1B1 at clinically relevant concentrations.

Patients with chronic inflammation are at risk for developing cardiovascular disease, and they may be prescribed statins while taking upadacitinib. Atorvastatin and rosuvastatin, 2 commonly prescribed statins, function as competitive inhibitors of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes a rate-limiting step in cholesterol biosynthesis and reduces plasma low-density lipoprotein cholesterol concentrations associated with cardiovascular disease. Atorvastatin is extensively metabolized, primarily by CYP3A, to a number of metabolites. Approximately 70% of circulating HMG-CoA reductase inhibitory activity can be attributed to the active metabolites of atorvastatin, including the main metabolite ortho-hydroxyatorvastatin. Both atorvastatin and its metabolites are substrates for cellular uptake through OATP1B1 and OATP1B3. Rosuvastatin, on the other hand, is not extensively metabolized, and the majority of the active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound. The main metabolite of rosvastatin, N-desmethyl rosvastatin, is formed principally by CYP2C9 and has minimal inhibitory activity of HMG-CoA reductase compared to rosvastatin. Rosuvastatin is a substrate for cellular uptake through OATP1B1 and cellular efflux through BCRP.

This study was conducted to evaluate the effect of administration of multiple doses of upadacitinib on the pharmacokinetics of rosvastatin and atorvastatin and the effect of single doses of these statins on the pharmacokinetics of upadacitinib at steady state. Results from this study informed the prescribing instructions on concomitant administration of upadacitinib with rosvastatin and atorvastatin.

Methods

The study was conducted at the AbbVie Clinical Pharmacology Research Unit (Grayslake, Illinois) in accordance with Good Clinical Practice guidelines and the ethical principles that have their origin in the Declaration of Helsinki. The protocol and informed consent form were approved by the institutional review board (Vista Medical Center East Institutional Review Board, Vista Health System, Waukegan, Illinois), and participants provided written informed consent before any study-related procedures were performed.

Study Subjects

Healthy men and women (postmenopausal or surgically sterile) aged 18 to 55 years with a body mass index between 18 and 29 kg/m² were enrolled on the basis of screening results of a medical history, physical examination, vital signs assessments, laboratory profile, and a 12-lead electrocardiogram (ECG). Subjects with any history or evidence of active tuberculosis (TB) disease, latent TB infection, or a history of a positive TB skin test; any active or recurrent viral infection; significant illness/infection/major febrile illness; hospitalization; or who had any surgical procedure within 30 days before the first dose of the study drug were excluded from this study. Use of tobacco or nicotine-containing products, a history of clinically significant drug or alcohol use within 180 days before the first dose of study drug administration, or a positive screen for drugs of abuse/alcohol/nicotine resulted in those subjects being excluded from this study. Subjects were also excluded if they had received an organ transplant or used any over-the-counter or prescription medication, vitamins, or herbal supplements on a regular basis. Use of any known inhibitors or inducers of drug-metabolizing enzymes within 30 days before the study start and through the course of the study was prohibited. Subjects with prior exposure to upadacitinib or any other Janus kinase inhibitor within the 3 months before the first dose of the study drug administration were also excluded from participation in the study.

Study Design

This was a phase 1, single-center, open-label study to evaluate the effects of coadministration of upadacitinib on the pharmacokinetics of rosvastatin and atorvastatin as well as the effect of single doses of these statins on upadacitinib steady-state pharmacokinetics (Figure 1). The study consisted of 2 parts, with 2 treatment periods in each study part. A single dose of rosvastatin (5 mg) or atorvastatin (10 mg) was administered on day 1 of period 1 for part 1 and part 2, respectively. During period 2 of both parts of this study, upadacitinib 30 mg was dosed alone once daily for
10 days and rosuvastatin (in part 1) or atorvastatin (in part 2) was administered 1 hour following upadacitinib dosing on day 7. Part 1 was conducted in 12 healthy subjects, and part 2 was conducted in 24 healthy subjects, given the higher within-subject variability in atorvastatin pharmacokinetics compared to rosuvastatin.29,30 All study drugs were administered orally with \( \approx 240 \text{mL} \) of water under nonfasting conditions. Rosuvastatin and atorvastatin were administered in period 2 one hour after administration of upadacitinib extended-release formulation to account for the delay in upadacitinib absorption from the extended-release formulation under nonfasting conditions.

**Pharmacokinetic Sampling and Bioanalysis**

Serial blood samples were collected in dipotassium ethylenediaminetetraacetic acid–containing collection tubes to determine plasma concentrations of upadacitinib and rosuvastatin and sodium heparin-containing collection tubes to determine the plasma concentrations of atorvastatin and ortho-hydroxyatorvastatin. For rosuvastatin, samples were collected starting on day 1 of period 1 and day 7 of period 2 at 0 (before dosing), 0.5, 1, 2, 3, 4, 5, 6, 8, 11, 15, 23, 36, 48, 72, and 96 hours after dosing rosuvastatin. For the atorvastatin and ortho-hydroxyatorvastatin, samples were collected starting on day 1 of period 1 and day 7 of period 2 at 0 (before dosing), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 11, 15, 23, 36, 48, 72, and 96 hours after dosing atorvastatin. For upadacitinib, samples were collected on day 6 of period 2 at 0 (before dosing), 0.5, 1, 2, 3, 4, 7, 9, 12, and 16 hours after upadacitinib dosing. Additional samples were collected on day 7 of period 2 before upadacitinib dosing (0 hour; 24 hours after day 6 upadacitinib dose); at 0.5 and 1 hour before the statin dose; and at 2, 3, 4, 7, 9, 12, 16, and 24 hours after upadacitinib dosing.

Plasma samples for upadacitinib were stored frozen at \( \approx -20^\circ\text{C} \) and plasma samples for rosuvastatin, atorvastatin, and ortho-hydroxyatorvastatin were stored at \( -70^\circ\text{C} \) until analyzed. Plasma concentrations of upadacitinib were determined using a validated salt-assisted liquid/liquid extraction with liquid chromatography method with tandem mass spectrometry detection by the Drug Analysis Department at AbbVie (North Chicago, Illinois) as described previously.31 Plasma concentrations of rosuvastatin, atorvastatin, and ortho-hydroxyatorvastatin were determined using a validated liquid chromatography method with tandem mass spectrometry detection (PPD Inc, Middleton, Wisconsin).

For the atorvastatin/ortho-hydroxyatorvastatin, the analytes of interest were extracted by liquid/liquid extraction from 100-\( \mu\text{L} \) sample volume combined with 50 \( \mu\text{L} \) of the internal standards (atorvastatin-\( \text{d}_4 \), ortho-hydroxyatorvastatin-\( \text{d}_3 \) ). Chromatographic separation for atorvastatin/ortho-hydroxyatorvastin was achieved using a Betasil C18 column (5 \( \mu\text{m} \), 2.1 × 50 mm; Thermo Fisher Scientific, Waltham, Massachusetts) and gradient mobile phase. Mobile phase A consisted of 1000/1 water:formic acid (v/v), mobile phase B consisted of 500:500:1 acetonitrile:methanol:formic acid (v/v/v), and mobile phase C consisted of 90/10 acetone:water (v/v). Chromatographic separation for rosuvastatin was achieved using a Gemini C18 column (5 \( \mu\text{m} \), 2 × 50 mm; Phenomenex, Torrance, California) and gradient mobile phase. Mobile phase A consisted of 40/60/0.05 methonal:water:1.0 M ammonium acetate, 2% acetic acid to pH 6 (v/v/v); and mobile phase B consisted of 100% methanol. An API 3000 mass spectrometer (AB Sciex, Framingham, Massachusetts) employing electrospray ionization in positive ion mode was used to monitor the analyte for atorvastatin/ortho-hydroxyatorvastin. Multiple reaction monitoring transitions were m/z 559.2 → 440.3 for atorvastatin and 575.3 → 440.3 for ortho-hydroxyatorvastin. For atorvastatin, the lower limit of quantification was 0.100 ng/mL, and intraday precision and accuracy/bias as demonstrated by the performance of the quality control samples were between 1.98% and 5.97% and between \(-7.91\% \) and 6.41%, respectively. Interday precision and accuracy/bias for atorvastatin were between 4.40% and 7.51% and between \(-1.58\% \) and 0.334%, respectively. For ortho-hydroxyatorvastin, the lower limit of quantification was 0.100 ng/mL, and intraday precision and accuracy/bias as demonstrated by the performance of the quality control samples were between 2.43% and 6.36% and between \(-2.61\% \) and 9.64%, respectively. Interday precision and accuracy/bias for
orthohydroxyatorvastatin were between 4.38% and 5.95% and between 2.39% and 5.89%, respectively.

For the rosuvastatin assay, the analyte of interest was extracted by liquid/liquid extraction from 300-μL sample volume combined with 30 μL of the internal standard (rosuvastatin-d₆). Chromatographic separation for rosuvastatin was achieved using a Gemini C18 column (5 μm, 2 × 50 mm; Phenomenex) and gradient mobile phase. Mobile phase A consisted of 40/60/0.05 methanol:water:1.0M ammonium acetate, 2% acetic acid to pH 6 (v/v/v); and mobile phase B consisted of 100% methanol. An API 3000 mass spectrometer (AB Sciex) employing electrospray ionization in negative ion mode was used to monitor the analyte for rosuvastatin. Multiple reaction monitoring transitions were m/z 480.4 → 418.2 for rosuvastatin. The lower limit of quantification was 0.100 ng/mL. Intraday assay precision and accuracy/bias for rosuvastatin, as demonstrated by the performance of the quality control samples, were between 1.01% and 16.2% and between −9.80% and 3.41%, respectively. Interday precision and accuracy/bias for rosuvastatin were between 1.95% and 11.7% and between −2.41% and 1.34%, respectively.

Pharmacokinetic Analyses
Pharmacokinetic parameters for upadacitinib, rosuvastatin, atorvastatin and ortho-hydroxyatorvastatin were estimated using noncompartmental methods in Phoenix WinNonlin version 6.4 (Pharsight, A Certara Company, St. Louis, Missouri). Pharmacokinetic parameters included the Cmax, time to reach Cmax, the area under the plasma concentration–time curve (AUC) from time 0 to the last measurable time point (AUCₜ), and from time 0 to infinity (AUCinf), and the terminal-phase elimination half-life. Upadacitinib pharmacokinetic parameters included Cmax, time to reach Cmax, observed concentration 24 hours after dosing, apparent oral clearance, and AUC from time 0 to 24 hours after dosing (AUC0-24).

Statistical Analyses
All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina). The effect of upadacitinib on pharmacokinetics of rosuvastatin and atorvastatin was assessed through a repeated measures analysis for the natural logarithms of Cmax and AUC using data from day 1 of period 1 and day 7 of period 2. A separate analysis was performed for each part, and the model had study period as a fixed effect.

The bioavailability of the rosuvastatin or atorvastatin when administered concomitantly with upadacitinib (day 7 of period 2) relative to that of the rosuvastatin or atorvastatin alone (day 1 of period 1) was assessed by calculating the difference of the least squares means obtained from the repeated measures analyses of the natural logarithms of Cmax and AUC. The 90% confidence intervals (CIs) were obtained for those ratio estimates by taking the antilogarithm of the upper and lower limits of CIs for the difference of the least squares means on the logarithmic scale. Similar analyses were performed to assess the change in ratio of ortho-hydroxyatorvastatin to atorvastatin AUC when atorvastatin was administered with upadacitinib relative to when administered alone (part 2; day 7 of period 2 relative to day 1 of period 1) and to assess the effect of a single doses of rosuvastatin and atorvastatin on the steady-state plasma exposures of upadacitinib (day 7 of period 2 relative to day 6 of period 2 in each part).

Safety Monitoring
Routine safety evaluations, which included adverse event monitoring, physical examinations, vital sign measurements, ECG assessments, and clinical laboratory tests (hematology, chemistry, and urinalysis) were performed throughout the course of the study.

Results
Subject Disposition
A total of 36 healthy subjects (3 women and 33 men) were enrolled in the study (12 subjects in part 1 and 24 subjects in part 2). The mean age of the 12 subjects in part 1 was 36 years (range, 24-53), and the mean weight was 79.2 kg (range, 58.8-112.1). In part 1, 4 subjects were White (33%), 7 subjects were Black (58%), and 1 subject was an American Indian/Alaska Native (8%). The mean age of the 24 subjects in part 2 was 35 years (range, 23-54), and the mean weight was 76.7 kg (range, 59.8-101.0). In part 2, 12 subjects were White (50%), 10 subjects were Black (42%), and 2 were multiracial (8.3%). All subjects completed the study and were included in the analyses.

Pharmacokinetics of Rosuvastatin and Atorvastatin
The mean plasma concentration–time profiles for rosuvastatin and atorvastatin administered alone and with upadacitinib are shown on a linear and log-linear scale in Figures 2 and 3A, respectively, and the mean plasma concentration–time profiles for the active metabolite ortho-hydroxyatorvastatin following administration of atorvastatin alone and with upadacitinib are shown in Figure 3B. The pharmacokinetic parameters for rosuvastatin, atorvastatin, and ortho-hydroxyatorvastatin following the administration of atorvastatin with and without upadacitinib are presented in Table 1.

The ratios of central values and 90%CIs for the effect of upadacitinib on the Cmax, AUCₜ, and AUCinf for rosuvastatin, atorvastatin, and ortho-hydroxyatorvastatin are shown in Figure 4. Following the administration of multiple doses of upadacitinib
AUC: area under the plasma concentration–time curve from time 0 to infinity; AUCt: area under the plasma concentration–time curve from time 0 to the last measurable time point; Cmax: maximum observed plasma concentration; t1/2: terminal-phase elimination half-life; tmax: time to maximum observed plasma concentration.

b Median (minimum-maximum)

c Arithmetic mean ± pseudo-standard deviation.

d Ratio of metabolite (ortho-hydroxyatorvastatin) AUCt to parent drug (atorvastatin) AUCt.

e Ratio of metabolite (ortho-hydroxyatorvastatin) AUCinf to parent drug (atorvastatin) AUCinf.

Pharmacokinetics of Upadacitinib

The mean plasma concentration–time profiles for upadacitinib when it was administered alone (day 6 of period 2) and with rosuvastatin or atorvastatin (day 7 of period 2) are shown in Figure 5A and 5B respectively. The pharmacokinetic parameters of upadacitinib in the presence of either rosuvastatin or atorvastatin are presented in Table 2.

The ratios of central values and 90% CIs for upadacinib Cmax and AUC0–24 when upadacinib was administered with rosuvastatin and atorvastatin relative to when administered alone are presented in Figure 6. There was no relevant effect of rosuvastatin or atorvastatin on upadacinib Cmax and AUC0–24.
Table 2. Mean ± SD Pharmacokinetic Parameters of Upadacitinib Following the Administration of Upadacitinib 30 mg Once Daily Doses Alone and With Single Doses of Rosuvastatin and Atorvastatin

| Pharmacokinetic Parameters (Units) | Period 2, Day 6 Upadacitinib 30 mg Once Daily (N = 12) | Period 2, Day 7 Upadacitinib 30 mg Once Daily + Rosuvastatin 5 mg Single Dose (N = 12) | Period 2, Day 6 Upadacitinib 30 mg Once Daily (N = 24) | Period 2, Day 7 Upadacitinib 30 mg Once Daily + Atorvastatin 10 mg Single Dose (N = 24) |
|-----------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------|
| Cmax, ng/mL                      | 73.0 ± 23.6                                           | 80.9 ± 21.2                                                                         | 76.5 ± 16.1                                         | 73.2 ± 17.1                                                                         |
| tmax, h                          | 3.0 (1.0-4.0)                                         | 3.0 (2.0-4.0)                                                                       | 3.0 (2.0-4.0)                                       | 3.0 (2.0-7.0)                                                                       |
| AUC0-24, ng · h/mL               | 585 ± 153                                             | 567 ± 131                                                                          | 547 ± 112                                          | 533 ± 103                                                                           |
| C24, ng/mL                       | 5.17 ± 1.56                                           | 5.56 ± 1.52                                                                         | 4.30 ± 1.74                                        | 4.61 ± 1.67                                                                         |
| CL/F, L/h                        | 54.6 ± 14.4                                           | 55.9 ± 14.7                                                                         | 57.2 ± 12.3                                        | 58.4 ± 11.7                                                                         |

AUC0-24, area under the plasma concentration–time curve from time 0 to 24 hours after dosing; C24, observed concentration 24 hours after dosing; Cmax, maximum observed plasma concentration; CL/F, apparent oral clearance; tmax, time to maximum observed plasma concentration.  

*Median (minimum-maximum).*

Figure 2. Mean rosuvastatin plasma concentration–time profiles following administration of a single dose of 5 mg rosuvastatin alone (open circles) and with multiple once-daily doses of 30 mg upadacitinib (filled circles). Plots are on linear-linear and log-linear scales (inset).

Safety and Tolerability

There was no pattern to the adverse events reported, and no new safety findings for upadacitinib, alone or with the statins, were identified in this study. The regimens were well tolerated by the healthy subjects in this study. No subject had a severe or serious adverse event; discontinued from the study due to an adverse event; or had a clinically relevant change in vital signs, laboratory values, or ECGs. Three subjects reported the occurrence of a treatment-emergent adverse event of headaches (grade 1 or grade 2) during treatment with upadacitinib and atorvastatin. During treatment with rosuvastatin and upadacitinib, 1 patient reported constipation (grade 1).

Discussion

This study characterized the effect of coadministration of upadacitinib 30 mg once daily using the extended-release formulation on the pharmacokinetics of rosuvastatin (a substrate for OATP1B1 and BCRP) and atorvastatin (a substrate for CYP3A, OATP1B1, and OATP1B3) in healthy subjects. The study results showed no increase in rosuvastatin and atorvastatin plasma exposures, which is consistent with expected lack of clinically relevant inhibition of the hepatic uptake transporter OATP1B1 and efflux transporter BCRP based on in vitro assessments and upadacitinib clinically relevant concentrations. Following the administration of upadacitinib 30 mg once daily, rosuvastatin and atorvastatin Cmax and AUC were slightly (11%-33%) lower when the statins were administered alone. This relatively small effect is within the reported intrasubject variability in rosuvastatin and atorvastatin plasma exposures (∼25% and 45%, respectively)29,32; therefore, it is not expected to be of clinical relevance. Additionally, the approved doses of rosuvastatin (5-40 mg) and atorvastatin (10-80 mg) are at 5- to 40-fold the estimated dose that results in 50% of the maximum effect and the pharmacologic effect of the statins is estimated to be near the plateau at this therapeutic dose range.33 Therefore, this relatively apparent small decrease in rosuvastatin and atorvastatin plasma exposures is not expected to result in clinically relevant effect on the efficacy of the statins or to require dose adjustment. The lack of change in the plasma levels of the atorvastatin active metabolite (ortho-hydroxyatorvastatin) further supports the lack of clinically relevant effect of upadacitinib on atorvastatin. The mechanism for the slight decrease in rosuvastatin plasma exposures is not clear. Upadacitinib
Figure 3. Mean atorvastatin (up triangles) and ortho-hydroxyatorvastatin (down triangles) plasma concentration–time profiles following the administration to healthy subjects of a single dose of 10 mg atorvastatin alone (open triangles) and with multiple once-daily doses of 30 mg upadacitinib (closed triangles). Plots are on linear-linear and log-linear scales (inset).

Figure 4. Effect of upadacitinib on the exposures of rosuvastatin, atorvastatin, and ortho-hydroxyatorvastatin. Symbols and lines represent ratio of central values and 90% confidence intervals for maximum observed plasma concentration ($C_{\text{max}}$; blue circles), area under the plasma concentration–time curve from time 0 to the last measurable time point (AUC$_{\text{t}}$; orange squares), and area under the plasma concentration–time curve from time 0 to infinity (AUC$_{\text{inf}}$; green triangles) following the coadministration of the statins with upadacitinib versus administration of the statins alone.

is not known to induce BCRP or OATP1B, which could have been a potential reason for a decrease in rosuvastatin exposures, and there is no clear evidence supporting that OATP1B transporters can be induced in vivo. The relatively small decrease in atorvastatin plasma exposures can potentially be due to a weak and non-clinically relevant induction of CYP3A with multiple doses of upadacitinib, which was observed also with midazolam in a cocktail drug-drug interaction study. In another clinical drug interaction study, upadacitinib had no effect on the plasma exposures of the oral contraceptives ethinylestradiol and levonorgestrel, which are partially metabolized by CYP3A. Interoccasion variability in the statin exposures could have also contributed to the relatively small change observed in exposures, particularly given the fixed-sequence design of the study. Results from this study supported that upadacitinib has no clinically relevant effect on rosuvastatin and atorvastatin and can be administered concomitantly with these drugs.

At the time of conducting this study, upadacitinib was being evaluated in phase 3 clinical trials in subjects with RA at doses of 15 mg and 30 mg once daily using the extended-release formulation. Therefore, the dose of upadacitinib evaluated for potential effects on rosuvastatin and atorvastatin was the 30 mg (the higher of the 2 potential clinical dose levels). For rosuvastatin and atorvastatin, the dose used in the study corresponds to the recommended starting daily doses of each of the 2 drugs for the treatment of dyslipidemia (5 mg and 10 mg, respectively). The main objective of the study was to evaluate the effects of upadacitinib on rosuvastatin and atorvastatin, particularly to confirm the lack of clinically relevant inhibition of OATP1B transporters in vivo at clinically relevant exposures. Therefore, the doses evaluated of rosuvastatin and atorvastatin were the starting, rather than the maximum, therapeutic doses to ensure that atorvastatin and rosuvastatin exposures stay within safe and acceptable ranges in case of increased exposures due to OATP1B inhibition. For the effects of rosuvastatin and atorvastatin on upadacitinib pharmacokinetics, there is no mechanistic reason to expect that higher doses of rosuvastatin or atorvastatin will have a relevant effect on upadacitinib plasma exposures, as neither rosuvastatin nor atorvastatin is...
Figure 5. Mean upadacitinib plasma concentration versus time profiles at steady state following the administration of multiple once-daily doses of 30 mg upadacitinib alone (open squares) and with single doses of (A) rosuvastatin and (B) atorvastatin (closed squares). Plots are on linear-linear and log-linear scales (inset).

known to be an inhibitor of CYP3A, which is the main enzyme involved in upadacitinib metabolism.12,17

In this study, upadacitinib was administered for 6 days before being administered concomitantly with rosuvastatin and atorvastatin. Upadacitinib demonstrates no significant accumulation in plasma with repeated once-daily dosing of the extended-release formulation, and steady state is achieved within 4 days of once-daily dosing.9 Therefore, it is expected that steady-state upadacitinib exposures were achieved by the day of coadministration with rosuvastatin and atorvastatin (day 7 of period 2). Daily administration of the upadacitinib alone continued for 3 additional days (days 8-10 of period 2) after the statin administration to ensure that any potential effect of upadacitinib on statin clearance was sustained during statin washout.

Figure 6. Effect of rosuvastatin or atorvastatin on the exposures of upadacitinib. Symbols and lines represent ratio of central values and 90%CIs for maximum observed plasma concentration (C_{max}; blue circles) and area under the plasma concentration–time curve from time 0 to 24 hours after dosing (AUC_{0-24}; orange squares) following the coadministration of upadacitinib with either statin versus administration of upadacitinib alone.

Therefore, the trial design ensured characterization of the maximum potential effect of upadacitinib 30 mg once daily on rosuvastatin and atorvastatin pharmacokinetics. Doses of the statins were administered 1 hour after administration of upadacitinib extended release to ensure assessment of maximum inhibition potential between the agents.

The doses of rosuvastatin, atorvastatin, and upadacitinib that were administered alone or in combination were generally well tolerated by the subjects in this study. No clinically significant changes in vital signs or laboratory measurements were observed during the course of the study, and no new safety findings were identified from this study. Mild or moderate headaches were the most common adverse events and there was no pattern for time dependency for the incidence of this adverse event. These findings are consistent with previous phase 1 studies.16

Conclusions

Following multiple upadacitinib 30 mg once daily dose administrations, there was no increase in rosuvastatin or atorvastatin exposures, indicating lack of inhibition of OATP1B or BCRP in vivo by upadacitinib. Rosuvastatin C_{max} and AUC_{inf} were 23% and 33% lower, respectively, and atorvastatin C_{max} and AUC_{inf} was lower by 11% and 23%, respectively, when they were coadministered with upadacitinib relative to when administered alone. AUC and C_{max} for ortho-hydroxyatorvastatin (the major active metabolite for atorvastatin) remained unchanged for atorvastatin concomitant administration with upadacitinib relative to atorvastatin administration alone. This apparent small
References

1. Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. *Gastroenterology*. 2020;158(8):2123-2138.e8.

2. Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2020;145(3):877-884.

3. van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. *Lancet*. 2019;394(10214):2108-2117.

4. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2018;391(10139):2503-2512.

5. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. *Lancet*. 2018;391(10139):2513-2524.

6. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol*. 2019;71(11):1788-1800.

7. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. *Lancet*. 2019;393(10188):2303-2311.

8. van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. *Arthritis Rheumatol*. 2020;72(10):1607-1620.

9. Mohamed MF, Zeng J, Marroum PJ, Song IH, Othman AA. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. *Clin Pharmacol Drug Dev*. 2019;8(2):208-216.

10. Mohamed MF, Klünder B, Camp HS, Othman AA. Exposure-response analyses of upadacitinib efficacy in phase II trials in rheumatoid arthritis and basis for phase III dose selection. *Clin Pharmacol Ther*. 2019;106(6):1319-1327.

11. Nader A, Mohamed MF, Winzenborg I, et al. Exposure-response analyses of upadacitinib efficacy and safety in phase II and III studies to support benefit-risk assessment in rheumatoid arthritis. *Clin Pharmacol Ther*. 2020;107(4):994-1003.

12. Mohamed MF, Klünder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. *Clin Pharmacokinet*. 2020;59(5):531-544.

13. Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA. Pharmacokinetics of upadacitinib in...
healthy subjects and subjects with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials. J Clin Pharmacol. 2020;60(4):528-539.

14. Klünder B, Mittrapalli RK, Mohamed MF, Friedel A, Noertersheuser P, Othman AA. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019;58(8):1045-1058.

15. Klunder B, Mohamed MF, Othman AA. Population Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018;57(8):977-988.

16. Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547-1558.

17. Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83(10):2242-2248.

18. Mohamed MF, Feng T, Enejesa JV, Fisniku O, Othman AA. Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: a study with the modified Cooperstown 5+1 cocktail. J Clin Pharmacol. 2020;60(1):86-95.

19. Mohamed MF, Trueman S, Feng T, Friedman A, Othman AA. The JAK1 inhibitor upadacitinib has no effect on the pharmacokinetics of levonorgestrel and ethinylestradiol: a study in healthy female subjects. J Clin Pharmacol. 2019;59(4):510-516.

20. Ancia R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28.

21. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15(5):467-478.

22. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64(1):58-65.

23. Lennerng H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141-1160.

24. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343-370.

25. Hua WJ, Hua WX, Fang HJ. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther. 2012;30(5):e234-e241.

26. Ricci G, Ciccone MM, Giordano P, Cortese F. Statins: pharmacokinetics, pharmacodynamics and cost-effectiveness analysis. Curr Vasc Pharmacol. 2019;17(3):213-221.

27. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002;20(4):303-328.

28. Elsby R, Martin P, Surry D, Sharma P, Fenner K. Solitary Inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos. 2016;44(3):398-408.

29. Hwang YG, Yu KS, Lee S. Comparison of the Pharmacokinetics of highly variable drugs in healthy subjects using a partial replicated crossover study: a fixed-dose combination of fimasartan 120 mg and atorvastatin 40 versus separate tablets. Drug Des Devel Ther. 2020;14:1953-1961.

30. Nwe HH, Bullman JN, Joshi SM, Stylianou A, Kapsi SG. The relative bioavailability of 2 prototype fixed-dose combination formulations for amlodipine and rosuvastatin in healthy White and Chinese subjects. Clin Pharmacol Drug Dev. 2016;5(2):131-140.

31. Mohamed MF, Minocha M, Trueman S, et al. Characterization of the effect of upadacitinib on the pharmacokinetics of bupropion, a sensitive cytochrome P450 2B6 probe substrate. Clin Pharmacol Drug Dev. 2021;10(3):299-306.

32. Zava D. A Bioequivalence study of two formulations of rosuvastatin. J Bioeq Stud. 2019;5(1).

33. Dimmitt SB, Stampfer HG, Warren JB. The pharmacodynamic and clinical trial evidence for statin dose. Br J Clin Pharmacol. 2018;84(6):1128-1135.

34. Zamek-Gliszczynski MJ, Patel M, Yang X, et al. Intestinal P-gp and putative hepatic OATP1B induction: international transporter consortium perspective on drug development implications. Clin Pharmacol Ther. 2021;109(1):55-64.

35. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69-76.

36. Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809-822.